SCHEMBL5879176

SCHEMBL5879176

COc1cc2[nH]c3c4c(=O)[nH]c(=O)c4c4c(=O)[nH]c(=O)c4c3c2cc1OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSV O60911 2/20 0.63
CTSL P07711 2/20 0.63
SRD5A1 P18405 1/20 0.51
SRD5A2 P31213 1/20 0.51
ALDH1A1 P00352 3/20 0.46
CHEK1 O14757 1/20 0.45
RET P07949 1/20 0.44
KMT2A Q03164 2/20 0.43
ELANE P08246 1/20 0.43
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
KDM4E B2RXH2 2/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879177 0.83 ALDH1A1 (0.56) ALDH1A1CHEK1RETKMT2AKDM4E
SCHEMBL7255463 0.81 CTSV (0.68) CTSVCTSLSRD5A1SRD5A2ALDH1A1
SCHEMBL1943022 0.81 CTSV (0.68) CTSVCTSLSRD5A1SRD5A2ALDH1A1
SCHEMBL12047200 0.78 CTSV (0.68) CTSVCTSLSRD5A1SRD5A2ALDH1A1
SCHEMBL5879262 0.78 CTSV (0.61) CTSVCTSLALDH1A1CHEK1HPGD
SCHEMBL5879186 0.78 MAOA (0.58) CTSVCTSLSRD5A2ALDH1A1CHEK1
SCHEMBL15831877 0.76 CTSV (0.65) CTSVCTSLSRD5A1SRD5A2ALDH1A1
SCHEMBL5879271 0.75 ADORA3 (0.53) CTSVCTSLSRD5A2ALDH1A1CHEK1
SCHEMBL20580714 0.75 CTSV (0.55) CTSVCTSLSRD5A1SRD5A2ALDH1A1
SCHEMBL20580807 0.74 CTSV (0.60) CTSVCTSLSRD5A1SRD5A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CTSV 4382/4885CTSL 4574/4885SRD5A1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.